Severe acute interstitial pneumonia and gefitinib

Inoue, Akira; Saijo, Yasuo; Maemondo, Makoto; Gomi, Katsushige; Tokue, Yutaka; Kimura, Yuichiro; Ebina, Masahito; Kikuchi, Toshiaki; Moriya, Takuya; Nukiwa, Toshihiro

doi:10.1016/s0140-6736(03)12190-3

Cited by 418 publications

(261 citation statements)

References 1 publication

Supporting

Mentioning

241

Contrasting

Unclassified

Order By: Relevance

“…A further patient experienced grade 3 gastrointestinal ulcer and grade 4 anaemia and terminated gefitinib treatment on day 56 because of PD. Interstitial lung disease is the most problematic toxicity in gefitinib treatment in Japan (Inoue et al, 2003). In the present trial, one patient experienced grade 1 ILD on day 30, leading to the termination of gefitinib treatment.…”

Section: Safety and Toxicitymentioning

confidence: 66%

See 1 more Smart Citation

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

et al. 2006

View full text Add to dashboard Cite

Retrospective analysis has shown that activating mutations in exons 18 -21 of the epidermal growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a phase II trial to evaluate the efficacy and safety of gefitinib as first-line therapy for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. Patients with stage IIIB or IV chemotherapy-naïve NSCLC with EGFR mutation were treated with 250 mg gefitinib daily. For mutational analysis, DNA was extracted from paraffin-embedded tissues and EGFR mutations were analysed by direct sequence of PCR products. Twenty (24%) of the 82 patients analysed had EGFR mutations (deletions in or near E746-A750, n ¼ 16; L858R, n ¼ 4). Sixteen patients were enrolled and treated with gefitinib. Twelve patients had objective response and response rate was 75% (95% CI, 48 -93%). After a median follow-up of 12.7 months (range, 3.1 -16.8 months), 10 patients demonstrated disease progression, with median progression-free survival of 8.9 months (95% CI, 6.7 -11.1 months). The median overall survival time has not yet been reached. Most of the toxicities were mild. This study showed that gefitinib is very active and well tolerated as first-line therapy for advanced NSCLC with EGFR mutations.

show abstract

Section: Safety and Toxicitymentioning

confidence: 66%

“…Interstitial lung disease is the most problematic toxicity in gefitinib treatment in Japan where an incidence of 3.5% and a fatality rate of 1.6% have been reported (Inoue et al, 2003;Ando et al, 2006). Accordingly, in the present trial, we planned to conduct biweekly chest CT for early detection of ILD during the initial treatment period.…”

Section: Discussionmentioning

confidence: 99%

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

et al. 2006

View full text Add to dashboard Cite

show abstract

“…These findings suggest treatment with gefitinib may improve survival after bone metastasis. However, interstitial pneumonia remains a serious side effect [8]; furthermore, it is reported gefitinib is less effective in patients without the EGFR gene [12]. Therefore, indications for treatment with gefitinib should be considered carefully before improvement in survival can be expected.…”

Section: Discussionmentioning

confidence: 99%

Predictors of Survival in Patients With Bone Metastasis of Lung Cancer

Sugiura

Yamada

Sugiura³

et al. 2008

Clinical Orthopaedics &Amp; Related Research

232

192

View full text Add to dashboard Cite

The prognosis of patients with bone metastasis from lung cancer has not been well documented. We assessed the survival rates after bone metastasis and prognostic factors in 118 patients with bone metastases from lung cancer. The cumulative survival rates after bone metastasis from lung cancer were 59.9% at 6 months, 31.6% at 1 year, and 11.3% at 2 years. The mean survival was 9.7 months (median, 7.2 months; range, 0.1-74.5 months). A favorable prognosis was more likely in women and patients with adenocarcinoma, solitary bone metastasis, no metastases to the appendicular bone, no pathologic fractures, performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor. Analyses of single and multiple variables indicated better prognoses for patients with adenocarcinoma, no evidence of appendicular bone metastases, and treatment with an epithelial growth factor receptor inhibitor. The mean survival period was longer in a small group treated with an epithelial growth factor receptor inhibitor than in the larger untreated group. The data preliminarily suggest treatment with an epithelial growth factor receptor inhibitor may improve survival after bone metastasis.

show abstract

“…Some cases have proved fatal while others have improved following gefitinib withdrawal, steroids and supportive measures. The incidence in Japan has been reported at 1.7% (Inoue et al, 2003). This is higher than that reported worldwide of 1% in over 92 000 patients and of 0.38% in 439 000 patients as part of the compassionate use programme (Forsythe and Faulkner, 2003).…”

Section: Gefitinib and Erlotinibmentioning

confidence: 87%

Epidermal growth factor receptor tyrosine kinase inhibitors

Ranson

2004

Br J Cancer

104

View full text Add to dashboard Cite

Activation of the epidermal growth factor receptor (EGFR) has been linked to tumour proliferation, invasion, metastasis and angiogenesis in epithelial tumours. Inhibitors of the EGFR have emerged as promising anticancer agents and two main approaches have been developed, humanised monoclonal antibodies and tyrosine kinase inhibitors. This review discusses the current status of EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have entered clinical development. EGFR-TKIs are generally well tolerated and can sometimes produce impressive tumour regression in patients with advanced non-small-cell lung cancer. However, highly predictive or surrogate markers of activity have not been identified and there remains a need for translational research in their future development.

show abstract

Severe acute interstitial pneumonia and gefitinib

Cited by 418 publications

References 1 publication

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

Predictors of Survival in Patients With Bone Metastasis of Lung Cancer

Epidermal growth factor receptor tyrosine kinase inhibitors

Contact Info

Product

Resources

About